Compare ISPR & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ISPR | ACRV |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.5M | 74.0M |
| IPO Year | 2023 | 2022 |
| Metric | ISPR | ACRV |
|---|---|---|
| Price | $1.48 | $1.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $4.90 | ★ $11.50 |
| AVG Volume (30 Days) | 15.8K | ★ 251.0K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.94 | 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $96,014,610.00 | N/A |
| Revenue This Year | $16.14 | N/A |
| Revenue Next Year | $8.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $1.27 |
| 52 Week High | $3.87 | $3.56 |
| Indicator | ISPR | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 51.72 | 38.70 |
| Support Level | $1.41 | $1.61 |
| Resistance Level | $1.65 | $2.21 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 43.25 | 15.47 |
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping products in the United States, Europe, Canada, and South Africa. Geographically, the company generates the majority of its revenue from Europe.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.